This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Eligibility requires evaluation by a licensed healthcare professional and is not guaranteed. Compounded medications are not FDA-approved finished products. Pricing and program details are subject to change — confirm current terms directly with each platform before enrolling. This article contains affiliate links.
Why This Comparison Exists — And Why It's Different in 2026
When readers ask me to compare Gala against the bigger-name platforms, there's a problem most comparison articles don't address: Hims and Ro have materially changed their programs in 2026. Following a March 2026 settlement related to compounded semaglutide, Hims wound down its compounded GLP-1 offering and shifted to a brand-name-only model. Ro has moved in a similar direction, now centering its program around FDA-approved medications with an insurance concierge component. Noom remains available as a compounded-plus-coaching hybrid, but its compounded tirzepatide availability should be confirmed at enrollment given the tightening regulatory environment around post-shortage compounding.
The practical consequence: Gala is now among the few platforms in this comparison set still offering compounded tirzepatide at a sub-$200 monthly price point with a bundled pricing model and no separate membership fee. That changes what the comparison actually means. This isn't brand vs. brand. It's compounded tirzepatide access (Gala) vs. brand-name programs with insurance infrastructure (Hims, Ro) vs. a coaching-integrated compounded semaglutide program (Noom).
For my full Gala program review, including the honest assessment of where it works and where to go in carefully: Gala GLP-1 Review 2026: What I Found After Researching It.
The 2026 Regulatory Context Every Comparison Needs
The FDA resolved the tirzepatide drug shortage in October 2024. That removed the primary legal basis for most 503A compounding pharmacies to produce it. The semaglutide shortage was resolved in early 2025, and a March 2026 settlement pushed Hims to wind down its compounded semaglutide program entirely. Throughout 2026, the FDA has continued enforcement actions against compounding pharmacies, narrowing the number of legitimate compounded GLP-1 sources.
This matters for two reasons. First, any platform still offering compounded tirzepatide — including Gala — is operating under a regulatory framework that has tightened significantly. Confirming the specific compounding pharmacy's current legal standing before enrolling is worth doing, and your prescribing clinician is the appropriate person to help with that. Second, the brand-name programs (Hims and Ro) are actually more stable in regulatory terms for 2026, because they're no longer relying on compounding frameworks that are under enforcement pressure. The trade-off is price: brand-name access at these platforms costs substantially more.
Gala GLP-1
Medication: Compounded tirzepatide — GLP-1/GIP dual agonist. Two tracks: standard and microdosing. Both require a licensed provider's prescription. Neither is FDA-approved. Pricing: Standard track $179/mo on 3-month plan (homepage); $199/mo per FAQ monthly rate — confirm at checkout. Microdosing track $149/mo on 3-month plan. No separate membership fee — medication access and provider support are bundled. Insurance: Cash-pay only. Coverage: All 50 states. Consultation: Synchronous or asynchronous depending on state and medication type. Billing: Refunds only on medical disqualification; no standard cancellation refunds; 72-hour pre-billing cancellation notice required. Independent reviews: 974 Trustpilot reviews, 4.4 rating. What's included: Licensed provider review, medication, dosage adjustments, async provider messaging, companion app.
What stands out in this context: Among the platforms in this comparison, Gala is the only one currently offering compounded tirzepatide (GLP-1/GIP dual agonist) as the primary medication track at a sub-$200 price point with no separate membership fee. The bundled pricing model is genuinely simpler to understand than the membership-plus-medication structures at Hims and Ro. What to verify: Given the tightened regulatory environment for compounded tirzepatide post-shortage, confirm the pharmacy's current regulatory standing with your provider before your first billing cycle processes.
Hims Weight Loss Program — 2026 Update
Medication: Brand-name only as of 2026 following the March settlement. Wegovy (semaglutide, injectable and oral), Zepbound (tirzepatide), orforglipron (oral GLP-1, approved early 2026). No longer offering compounded GLP-1 to new patients. Pricing: Medication prices are separate from a required Hims Weight Loss Membership ($39 first month, then $149/mo). Wegovy injectable: $299/mo. Zepbound: $399/mo. Orforglipron: from $149/mo. GLP-1 injectable plans start as low as $199/mo on a 6-month plan paid upfront per Hims's published pricing. True all-in floor: Approximately $348/mo for the entry injectable semaglutide option (medication + membership). FSA/HSA eligible for all medication costs. Insurance: Insurance billing operational for all branded products; Novo Nordisk Savings Card integration. Coverage: GLP-1s not yet available in all 50 states per published information — verify your state before starting. Support: App-based messaging with clinical team.
What stands out: FDA-approved medications with no compounding regulatory risk. Insurance integration means some patients pay significantly less than the listed cash prices, particularly for Wegovy with the Novo Nordisk Savings Card. Zepbound FDA-approval for obstructive sleep apnea (approved 2024) may provide additional coverage pathways for qualifying patients. Wegovy HD (7.2mg, higher-dose formulation approved April 2026) is available through Hims for patients needing maximum dose escalation. What to verify: The true monthly cost requires adding the $149/mo membership on top of medication cost — the headline medication prices do not include this. State availability before starting — GLP-1s are not yet in all states.
Ro Body Program — 2026 Update
Medication: Primarily FDA-approved brand-name GLP-1s: Wegovy (injectable and oral), Zepbound, Ozempic. Compounded semaglutide options still listed but availability has changed — confirm current status at enrollment. Pricing: Medication and membership are billed separately. Ro Body membership: $45 first month, then $149/mo (or as low as $74/mo on annual prepay plan). Wegovy injectable: $199/mo for first two months, $349/mo thereafter (cash-pay). Oral Wegovy pill: from $149/mo. Tirzepatide/Zepbound: $299/mo first month, $399-$449/mo thereafter. True all-in cash-pay floor: Approximately $344/mo for oral semaglutide entry (medication + monthly membership). Insurance: Insurance concierge team handles prior authorizations for brand-name medications. Some patients with qualifying insurance may pay as little as their copay for Wegovy or Zepbound. Coverage: Broad U.S. availability. What's included: Lab testing (metabolic panels, thyroid, kidney function at Quest or home collection), 1:1 coaching, weekly nurse check-ins, 12-month structured curriculum. Support: Coaching via app and video messaging.
What stands out: Among the platforms in this comparison, Ro is the most comprehensive for patients who want insurance-navigated access to FDA-approved brand-name medications with lab testing and structured coaching included. The monthly membership includes lab work that most platforms charge separately or don't offer at all — a genuine differentiator for patients with complex health histories who need monitoring. The insurance concierge can be valuable for patients whose plans cover GLP-1s for weight management, which varies significantly by plan. What to verify: The true monthly cost requires adding the membership fee to medication cost. The $199/mo Wegovy promotional price noted in research ended March 31, 2026 — verify current pricing at ro.co before enrolling.
Noom Med — What It Actually Offers
Medication: Multiple tiers. Microdose GLP-1Rx Program: compounded semaglutide capped at 0.6mg maximum dose; starting from $79/mo (3-week initial subscription, then $199/mo per updated March 2026 pricing). Full-dose compounded GLP-1 program: approximately $199/mo. Brand-name medications (Wegovy, Zepbound, Ozempic) via insurance pathway: starts at $69/mo for the telehealth-only plan, with medication cost depending on insurance coverage. Compounded tirzepatide: Availability should be confirmed at enrollment given the post-shortage regulatory environment. Noom's microdose program uses compounded semaglutide, not tirzepatide. Insurance: Brand-name pathway available; insurance concierge support for prior authorizations. Compounded programs are cash-pay. Coverage: Broad U.S. availability. What's included: Behavioral coaching using psychology-based (CBT-informed) tools is a core program feature, not an add-on. Unlimited clinician messaging, dedicated care team, GLP-1 Companion app, weekly nurse check-ins.
What stands out: Noom is the only platform in this comparison that treats behavioral psychology as a central component rather than an optional add-on. The coaching layer is designed around cognitive behavioral tools for appetite, habit formation, and long-term weight maintenance. Noom's own data, from a retrospective study of self-reported data, indicates that active Noom users lost meaningfully more weight than those prescribed GLP-1s without the Noom program — though this figure is from self-reported data, not an independently controlled trial, and Noom's own disclosures note this. For patients who want behavioral structure alongside medication, Noom's program design is genuinely differentiated. What to verify: Which specific medication will be prescribed for your situation — semaglutide vs. tirzepatide vs. brand-name, and whether the specific formulation you want is currently available. Pricing tiers are numerous; confirm the exact tier that applies to your plan at enrollment.
How to Choose in 2026
If you specifically want compounded tirzepatide (GLP-1/GIP dual agonist) at the lowest current cash-pay price: Gala is the most relevant option in this comparison. Confirm the pharmacy's regulatory standing with your provider before starting. Understand the no-refund-on-standard-cancellation billing policy before your first payment processes. My full review covers the details: Gala GLP-1 Review 2026.
If you want FDA-approved brand-name GLP-1 medication and have commercial insurance or the Lilly/Novo savings card: Hims and Ro are the more relevant options. Hims's Novo Nordisk partnership means Wegovy is available with savings card integration. Ro's insurance concierge actively handles prior authorizations. Neither requires you to navigate the compounding regulatory uncertainty. The true all-in monthly cost is substantially higher than Gala, but the medication regulatory standing is different.
If you want structured behavioral coaching alongside your medication: Noom Med is the only platform in this comparison built around that combination. The coaching isn't a chatbot or a basic tracking app — it's a structured CBT-informed curriculum. If you've tried GLP-1 programs before without the behavioral component and struggled with long-term adherence, Noom's program design addresses exactly that gap. The microdose entry point at $79/mo is also the lowest cash-pay entry of any option in this comparison.
If you want the most comprehensive program including labs, coaching, and insurance navigation: Ro Body's membership includes lab testing (at Quest or via home collection) that other platforms in this comparison don't provide. The combined insurance concierge plus labs plus coaching structure makes Ro the closest thing to a managed care program in this comparison set. The price reflects that.
If you're in Louisiana specifically: Gala covers all 50 states. Wellorithm excludes Louisiana. Hims's state availability should be verified. Ro has broad coverage. Noom Med has broad coverage.
For the direct Gala-vs.-Wellorithm comparison specifically: Gala GLP-1 vs. Wellorithm: Two Compounded Programs Compared. For the broader telehealth landscape including programs not in this comparison: Best GLP-1 Telehealth Programs 2026: What to Know Before You Choose. For side effects and contraindications to review before starting any program: Gala GLP-1 Side Effects: What to Know Before You Start.
Frequently Asked Questions
How does Gala GLP-1 compare to Hims for weight loss in 2026?
Gala and Hims are now in different product categories following Hims's 2026 transition to brand-name-only medications. Gala offers compounded tirzepatide starting at $179/mo (bundled pricing, no separate membership fee). Hims's brand-name options require a $149/mo membership on top of medication costs — Wegovy injectable is $299/mo, Zepbound is $399/mo. For cash-pay patients specifically seeking compounded tirzepatide at the lowest price point, Gala is the more relevant option. For patients who want FDA-approved brand-name medications with insurance support, Hims's new model is designed for that use case.
Is Ro Body or Gala GLP-1 better in 2026?
They serve different use cases. Gala is a compounded tirzepatide-focused platform at $179/mo with no membership fee. Ro Body is now primarily brand-name, with Wegovy from $199/mo plus a $145/mo membership fee, insurance concierge, labs, and structured coaching. Ro is the better fit for patients with insurance who want help navigating brand-name coverage. Gala is the better fit for cash-pay patients specifically seeking compounded tirzepatide access without a separate membership charge.
How does Noom Med compare to Gala GLP-1?
Noom Med and Gala have very different program structures. Noom's microdose program starts around $79/mo and bundles behavioral coaching, psychology-based tools, and clinician access with compounded semaglutide (capped at 0.6mg). Gala focuses on tirzepatide (GLP-1/GIP dual agonist) without the behavioral coaching layer. Noom is the better fit for patients who want structured habit-change support alongside medication. Gala is a more streamlined option for patients who want compounded tirzepatide access without the coaching overhead.
Leave a Reply
You must be logged in to post a comment.